Shopping Cart
Remove All
Your shopping cart is currently empty
Polatuzumab vedotin-piiq is an antibody-drug conjugate targeting CD79b, obtained by conjugating a humanized anti-CD79b monoclonal antibody to the potent microtubule inhibitor monomethyl auristatin E (MMAE). Polatuzumab vedotin shows important application prospects in research related to large B-cell lymphoma (LBCL).
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Polatuzumab vedotin-piiq is an antibody-drug conjugate targeting CD79b, obtained by conjugating a humanized anti-CD79b monoclonal antibody to the potent microtubule inhibitor monomethyl auristatin E (MMAE). Polatuzumab vedotin shows important application prospects in research related to large B-cell lymphoma (LBCL). |
| In vivo | Polatuzumab vedotin-piiq administered as a single intravenous injection at 0.3, 1, 3, 6, and 12 mg/kg exhibits antitumor activity in a mouse xenograft model of human diffuse large B-cell lymphoma WSU‑DLCL2 [2]. |
| Synonyms | RG7596, Polivy, huMA79b.v28, DCDS4501A, Anti-CD79b Reference Antibody |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal, ADC |
| Endotoxin | <1.0 EU/mg |
| Conjucates | MMAE |
| Gene ID | |
| Uniprot ID | |
| Target | CD79b |
| Molecular Weight | 150.53 kDa |
| Isotype | IgG1 |
| Storage | -20°C for 1 year Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.